TX103 CAR-T cells for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new treatment called TX103 CAR-T cells for people with advanced solid tumors that have a specific protein (B7-H3). The goal is to see if these modified immune cells can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 74 years old.
- You have an advanced solid tumor (like ovarian, lung, colorectal, or head and neck cancer) that has spread, and standard treatments no longer work or you can't take them.
- A lab test on your tumor shows that at least 20% of the cancer cells have a protein called B7-H3 (CD276).
- You are in fairly good health (able to do daily activities on your own) and expected to live more than 6 months.
- You have good organ function (heart, liver, kidneys, blood counts) and can tolerate a blood-collection process called apheresis.
- You have not had CAR-T therapy or an organ transplant before, and you do not have untreated brain metastases or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR-T cell therapy designed to target two proteins, CD73 and AXL, found on cancer cells. It is for people with advanced or metastatic solid tumors (like bile duct, pancreatic, lung, breast, head and neck, or gynecologic cancers) who have not responded to standard treatment or have no standard first-line therapy available.
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called B7H3 on solid tumors. It is for people with advanced ovarian or peritoneal cancer who have not responded to standard treatments.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This trial tests a new CAR T-cell therapy made from your own immune cells to treat advanced cancers that have not responded to other treatments. It may be an option if your tumor has a specific target and you are otherwise healthy enough.
This trial tests a new type of immune cell therapy (NKG2D CAR-T cells) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if these specially engineered cells can shrink tumors or slow their growth.
This trial tests a new cell therapy called CHT102 for people with advanced solid tumors that have a certain marker (mesothelin). The treatment is for those who haven't responded to standard therapy or who don't have a standard first-line option.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.